Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of TGFbi NK Cells and Isatuximab for Myeloma Relapsed/Refractory to BCMA Targeting Therapy

NCT06203912 is registered in ClinicalTrials.gov with Elvira Umyarova as lead sponsor.

NCT NCT06203912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06203912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of TGFbi NK Cells and Isatuximab for Myeloma Relapsed/Refractory to BCMA Targeting Therapy
Lead sponsor
Elvira Umyarova
Phase
Phase 1
Overall status
Completed
Start date
March 5, 2024
Completion date
June 16, 2026
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent multiple myeloma, refractory multiple myeloma